Brii Biosciences Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BRIBF research report →
Price Chart
About the company
Brii Biosciences Limited, established in 2017 and headquartered in Beijing, China, is dedicated to advancing therapeutic solutions for infectious diseases and disorders affecting the central nervous system. Their diverse pipeline includes BRII-778 and BRII-732, both progressing through Phase I clinical trials for HIV patients. For Hepatitis B (HBV), they are evaluating BRII-179 and BRII-835 in a combined Phase 2 study; BRII-179 also stands as a recombinant protein-based HBV immunotherapeutic in Phase 1b/2a, while BRII-835 has completed Phase 2 for chronic HBV patients.
- CEO
- Zhi Hong
- IPO
- 2022
- Employees
- 75
- HQ
- Beijing, BE, CN
Get TickerSpark's AI analysis on BRIBF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $93.75M
- P/E
- -3.00
- PEG
- -0.04
- P/S
- 28.24
- P/B
- 0.24
- EV/EBITDA
- -0.07
- Div Yield
- 0.00%
- Gross Margin
- 63.08%
- Op Margin
- -1478.34%
- Net Margin
- -918.14%
- ROE
- -7.32%
- ROIC
- -12.47%
Latest fiscal year · YoY change
- Revenue
- $18.12M-63.7%
- Gross Profit
- $0-100.0%
- Op Income
- $-295,905,623
- Net Income
- $-216,878,992+57.3%
- EPS
- $-0.30+57.1%
- OCF Growth
- +23.1%
- FCF Growth
- +23.3%
- 52W High
- $0.26
- 52W Low
- $0.13
- 50D MA
- $0.13
- 200D MA
- $0.16
- Beta
- 1.20
- RSI (14)
- 30
- Avg Volume
- 112
No earnings-call transcripts are available for BRIBF yet.
- Free Float
- 78.0%
- Shares Outstanding
- 721.18M
- Float Shares
- 562.60M
Our BRIBF coverage
Recent articles, reports, and earnings notes.
No research on BRIBF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BRIBF report →Brii Bio Presents Late-Breaking Data from Its Phase 2 ENSURE Study at EASL Congress 2026, Further Supporting the Potential Role of BRII-179 in Achieving Durable Immunological Control of HBV
prnewswire.com · May 27
Brii Bio Presents Cross-Study Analysis of Post-Treatment HBsAg Rebound at APASL 2026
prnewswire.com · Apr 26
Brii Biosciences Limited (BRIBF) Q4 2025 Earnings Call Transcript
seekingalpha.com · Mar 20
Brii Biosciences Provides Corporate Updates and Reports Full Year 2025 Financial Results
prnewswire.com · Mar 19
Brii Biosciences Announces Publication of Phase 2 ENSURE Study Results in Nature Medicine
prnewswire.com · Nov 7
Brii Biosciences Provides Corporate Updates and Reports 2025 Interim Financial Results
prnewswire.com · Aug 21
Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China
prnewswire.com · Jul 3
Brii Bio Presents Late-Breaking Data from Its Ongoing Phase 2 ENSURE Study at EASL Congress 2025, Suggesting BRII-179's Role in Advancing Higher HBsAg Loss
prnewswire.com · May 7
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.